268 related articles for article (PubMed ID: 35792924)
41. Efficacy and safety of two pegfilgrastim biosimilars: Tripegfilgrastim and pegteograstim.
Kang KW; Lee BH; Jeon MJ; Yu ES; Kim DS; Lee SR; Sung HJ; Choi CW; Park Y; Kim BS
Cancer Med; 2020 Sep; 9(17):6102-6110. PubMed ID: 32633471
[TBL] [Abstract][Full Text] [Related]
42. Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses.
Hill G; Barron R; Fust K; Skornicki ME; Taylor DC; Weinstein MC; Lyman GH
J Med Econ; 2014 Jan; 17(1):32-42. PubMed ID: 24028444
[TBL] [Abstract][Full Text] [Related]
43. Pegfilgrastim for the prevention of chemotherapy-induced febrile neutropenia in patients with solid tumors.
Lambertini M; Ferreira AR; Del Mastro L; Danesi R; Pronzato P
Expert Opin Biol Ther; 2015; 15(12):1799-817. PubMed ID: 26488491
[TBL] [Abstract][Full Text] [Related]
44. Febrile neutropenia hospitalization due to pegfilgrastim on-body injector failure compared to single-injection pegfilgrastim and daily injections with reference and biosimilar filgrastim: US cost simulation for lung cancer and non-Hodgkin lymphoma.
McBride A; Krendyukov A; Mathieson N; Campbell K; Balu S; Natek M; MacDonald K; Abraham I
J Med Econ; 2020 Jan; 23(1):28-36. PubMed ID: 31433700
[No Abstract] [Full Text] [Related]
45. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
Aapro MS; Chaplin S; Cornes P; Howe S; Link H; Koptelova N; Mehl A; Di Palma M; Schroader BK; Terkola R
Support Care Cancer; 2023 Sep; 31(10):581. PubMed ID: 37728795
[TBL] [Abstract][Full Text] [Related]
46. Overuse and underuse of pegfilgrastim for primary prophylaxis of febrile neutropenia.
Zullo AR; Lou U; Cabral SE; Huynh J; Berard-Collins CM
J Oncol Pharm Pract; 2019 Sep; 25(6):1357-1365. PubMed ID: 30124123
[TBL] [Abstract][Full Text] [Related]
47. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
Wang XJ; Tang T; Farid M; Quek R; Tao M; Lim ST; Wee HL; Chan A
PLoS One; 2016; 11(2):e0148901. PubMed ID: 26871584
[TBL] [Abstract][Full Text] [Related]
48. Results of a prospective dose intensity and neutropenia prophylaxis evaluation programme (DIEPP) in cancer patients at risk of febrile neutropenia due to myelosuppressive chemotherapy.
Mądry R; Popławska L; Haslbauer F; Šafanda M; Ghizdavescu D; Benkovicova J; Csőszi T; Mihaylov G; Niepel D; Jaeger C; Frkanova I; Macovei A; Staudigl C
Wien Klin Wochenschr; 2016 Apr; 128(7-8):238-47. PubMed ID: 26745973
[TBL] [Abstract][Full Text] [Related]
49. Predictive Parameters of Febrile Neutropenia and Clinical Significance of G-CSF Receptor Signaling Pathway in the Development of Neutropenia during R-CHOP Chemotherapy with Prophylactic Pegfilgrastim in Patients with Diffuse Large B-Cell Lymphoma.
Kim DY; Nam J; Chung JS; Jeon BE; Lee JH; Jo JC; Kim SW; Shin HJ
Cancer Res Treat; 2022 Oct; 54(4):1256-1267. PubMed ID: 34990523
[TBL] [Abstract][Full Text] [Related]
50. Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer.
Ichimura T; Nomura H; Shimizu H; Machida Y; Suzuki K
Pharmazie; 2021 Sep; 76(9):450-454. PubMed ID: 34481537
[No Abstract] [Full Text] [Related]
51. Prophylactic pegfilgrastim reduces febrile neutropenia in ramucirumab plus docetaxel after chemoimmunotherapy in advanced NSCLC: post hoc analysis from NEJ051.
Miura K; Yamaguchi O; Mori K; Nakamura A; Tamiya M; Oba T; Yanagitani N; Mizutani H; Ninomiya T; Kajiwara T; Ito K; Miyanaga A; Arai D; Kodama H; Kobayashi K; Kaira K
Sci Rep; 2024 Feb; 14(1):3816. PubMed ID: 38360906
[TBL] [Abstract][Full Text] [Related]
52. [Comparison of Pegfilgrastim and Filgrastim for the Primary Prophylactic Effect for Preventing Febrile Neutropenia in Patients Undergoing Rituximab with Dose-adjusted EPOCH Chemotherapy].
Kataoka T; Sakurashita H; Taogoshi T; Nishigakiuchi R; Murase T; Izumitani S; Saeki Y; Matsuo H
Yakugaku Zasshi; 2019; 139(4):629-633. PubMed ID: 30930398
[TBL] [Abstract][Full Text] [Related]
53. A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.
Lee KH; Kim JY; Lee MH; Han HS; Lim JH; Park KU; Park IH; Cho EK; Yoon SY; Kim JH; Choi IS; Park JH; Choi YJ; Kim HJ; Jung KH; Kim SY; Oh DY; Im SA
Support Care Cancer; 2016 Apr; 24(4):1709-17. PubMed ID: 26423618
[TBL] [Abstract][Full Text] [Related]
54. Cost-effectiveness analysis of granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced febrile neutropenia in patients with breast cancer in Taiwan.
Tseng TH; Chiang SC; Hsu JC; Ko Y
PLoS One; 2024; 19(6):e0303294. PubMed ID: 38857244
[TBL] [Abstract][Full Text] [Related]
55. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.
Aapro M; Boccia R; Leonard R; Camps C; Campone M; Choquet S; Danova M; Glaspy J; Hus I; Link H; Sliwa T; Tesch H; Valero V
Support Care Cancer; 2017 Nov; 25(11):3295-3304. PubMed ID: 28842778
[TBL] [Abstract][Full Text] [Related]
56. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in patients with non-Hodgkin lymphoma (NADIR study).
Wolff T; Schulz H; Losem C; Reichert D; Hurtz HJ; Sandner R; Harde J; Grebhardt S; Potthoff K; Mueller U; Fietz T
Eur J Haematol; 2019 Feb; 102(2):174-181. PubMed ID: 30347466
[TBL] [Abstract][Full Text] [Related]
57. Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Yokoyama M; Kusano Y; Nishihara A; Inoue N; Nishimura N; Mishima Y; Terui Y; Nukada T; Nomura T; Hatake K
Support Care Cancer; 2020 Feb; 28(2):571-579. PubMed ID: 31093770
[TBL] [Abstract][Full Text] [Related]
58. A retrospective review of the real-world experience of the Pegfilgrastim biosimilar (Lapelga®) to the reference biologic (Neulasta®).
Wong G; Zhang L; Majeed H; Razvi Y; DeAngelis C; Lam E; McKenzie E; Wang K; Pasetka M
J Oncol Pharm Pract; 2022 Jan; 28(1):5-16. PubMed ID: 33215563
[TBL] [Abstract][Full Text] [Related]
59. Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy.
Bondarenko I; Gladkov OA; Elsaesser R; Buchner A; Bias P
BMC Cancer; 2013 Aug; 13():386. PubMed ID: 23945072
[TBL] [Abstract][Full Text] [Related]
60. Granulocyte colony-stimulating factors used in clinical practice: PoloNord Registry-Based Cohort Italian Study.
Fagnani D; Isa L; Verga MF; Nova P; Casartelli C; Filipazzi V; Danova M; Farina G; Pugliese P; Fava S; Bertolini A; Cimminiello C; Boracchi P; Marano G; Panzarino C;
Tumori; 2014; 100(5):491-8. PubMed ID: 25343541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]